Overview
| 别名 | Kazal-type serine protease inhibitor domain-containing protein 1 |
| 基因名 | KAZALD1 |
| UniProt ID | Q96I82 |
| 反应种属 | Human |
| 应用 | IHC-P |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG1 |
| 克隆号 | 2V9-T3-L8 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 32 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | IHC-1:200-1:250 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | Kazal type serine peptidase inhibitor domain 1 (KAZALD1) is a secreted protein encoded by the KAZALD1 gene, characterized by a multi-domain structure including an N-terminal insulin-like growth factor-binding domain, a central Kazal-type serine protease inhibitor and follistatin-like domain, and a C-terminal immunoglobulin-like domain. This configuration enables KAZALD1 to inhibit serine proteases, enzymes critical in processes such as digestion, coagulation, immune response, and cellular signaling. Functionally, KAZALD1 is involved in promoting osteoblast proliferation and matrix assembly during bone formation and regeneration, as suggested by studies on its mouse ortholog. Structurally, the Kazal domain contains conserved cysteine residues forming disulfide bonds that stabilize its inhibitory interaction with target proteases. Clinically, KAZALD1 is implicated in disease states including high-grade glioma, where its hypomethylation and overexpression correlate with increased tumor cell proliferation and poorer patient survival. It is also associated with multiple congenital anomalies due to deletions involving the gene locus. |
检测原理